Mirati Marks Another Milestone With Adagrasib
US FDA Grants Breakthrough Designation
Executive Summary
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.
You may also be interested in...
Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts
Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.
Zai Lab Joins Latest Oncology Race With Mirati KRAS Deal
Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.